Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program

Robert Ratner, Ronald B Goldberg, Steven Haffner, Santica Marcovina, Trevor Orchard, Sarah Fowler, Marinella Temprosa

Research output: Contribution to journalArticle

405 Citations (Scopus)

Abstract

OBJECTIVE - The Diabetes Prevention Program demonstrated the ability to delay or prevent type 2 diabetes in participants with impaired glucose tolerance (IGT). Participants with IGT are at high risk for cardiovascular disease (CVD), with a marked increase in the number and severity of CVD risk factors. We prospectively assessed the impact of our interventions on hypertension, dyslipidemia, and CVD events. RESEARCH DESIGN AND METHODS - The study group consisted of 3,234 individuals with IGT randomly assigned to receive intensive lifestyle intervention, metformin, or placebo. Annual assessment of blood pressure, lipids, electrocardiogram, and CVD events was undertaken. RESULTS - Hypertension was present in 30% of participants at study entry and then increased in the placebo and metformin groups, although it significantly decreased with intensive lifestyle intervention. Triglyceride levels fell in all treatment groups, but fell significantly more with intensive lifestyle intervention. Total cholesterol and LDL cholesterol levels were similar among treatment groups. Intensive lifestyle intervention significantly increased the HDL cholesterol level and reduced the cumulative incidence of the proatherogenic LDL phenotype B. At 3 years of follow-up, the use for pharmacologic therapy to achieve established goals in the intensive lifestyle group was 27-28% less for hypertension and 25% less for hyperlipidemia compared with placebo and metformin groups. Over an average of 3 years, 89 CVD events from 64 participants were positively adjudicated studywide, with no differences among treatment groups. CONCLUSIONS - Lifestyle intervention improves CVD risk factor status compared with placebo and metformin therapy. Although no differences in CVD events were noted after 3 years, achieved risk factor modifications suggest that longer intervention may reduce CVD event rates.

Original languageEnglish
Pages (from-to)888-894
Number of pages7
JournalDiabetes Care
Volume28
Issue number4
DOIs
StatePublished - Apr 1 2005
Externally publishedYes

Fingerprint

Metformin
Life Style
Cardiovascular Diseases
Glucose Intolerance
Placebos
Therapeutics
Hypertension
Aptitude
Dyslipidemias
Hyperlipidemias
LDL Cholesterol
Type 2 Diabetes Mellitus
HDL Cholesterol
Electrocardiography
Triglycerides
Research Design
Cholesterol
Blood Pressure
Phenotype
Lipids

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. / Ratner, Robert; Goldberg, Ronald B; Haffner, Steven; Marcovina, Santica; Orchard, Trevor; Fowler, Sarah; Temprosa, Marinella.

In: Diabetes Care, Vol. 28, No. 4, 01.04.2005, p. 888-894.

Research output: Contribution to journalArticle

Ratner, Robert ; Goldberg, Ronald B ; Haffner, Steven ; Marcovina, Santica ; Orchard, Trevor ; Fowler, Sarah ; Temprosa, Marinella. / Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. In: Diabetes Care. 2005 ; Vol. 28, No. 4. pp. 888-894.
@article{812451091bfe41e2814911685c6406bc,
title = "Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program",
abstract = "OBJECTIVE - The Diabetes Prevention Program demonstrated the ability to delay or prevent type 2 diabetes in participants with impaired glucose tolerance (IGT). Participants with IGT are at high risk for cardiovascular disease (CVD), with a marked increase in the number and severity of CVD risk factors. We prospectively assessed the impact of our interventions on hypertension, dyslipidemia, and CVD events. RESEARCH DESIGN AND METHODS - The study group consisted of 3,234 individuals with IGT randomly assigned to receive intensive lifestyle intervention, metformin, or placebo. Annual assessment of blood pressure, lipids, electrocardiogram, and CVD events was undertaken. RESULTS - Hypertension was present in 30{\%} of participants at study entry and then increased in the placebo and metformin groups, although it significantly decreased with intensive lifestyle intervention. Triglyceride levels fell in all treatment groups, but fell significantly more with intensive lifestyle intervention. Total cholesterol and LDL cholesterol levels were similar among treatment groups. Intensive lifestyle intervention significantly increased the HDL cholesterol level and reduced the cumulative incidence of the proatherogenic LDL phenotype B. At 3 years of follow-up, the use for pharmacologic therapy to achieve established goals in the intensive lifestyle group was 27-28{\%} less for hypertension and 25{\%} less for hyperlipidemia compared with placebo and metformin groups. Over an average of 3 years, 89 CVD events from 64 participants were positively adjudicated studywide, with no differences among treatment groups. CONCLUSIONS - Lifestyle intervention improves CVD risk factor status compared with placebo and metformin therapy. Although no differences in CVD events were noted after 3 years, achieved risk factor modifications suggest that longer intervention may reduce CVD event rates.",
author = "Robert Ratner and Goldberg, {Ronald B} and Steven Haffner and Santica Marcovina and Trevor Orchard and Sarah Fowler and Marinella Temprosa",
year = "2005",
month = "4",
day = "1",
doi = "10.2337/diacare.28.4.888",
language = "English",
volume = "28",
pages = "888--894",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "4",

}

TY - JOUR

T1 - Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program

AU - Ratner, Robert

AU - Goldberg, Ronald B

AU - Haffner, Steven

AU - Marcovina, Santica

AU - Orchard, Trevor

AU - Fowler, Sarah

AU - Temprosa, Marinella

PY - 2005/4/1

Y1 - 2005/4/1

N2 - OBJECTIVE - The Diabetes Prevention Program demonstrated the ability to delay or prevent type 2 diabetes in participants with impaired glucose tolerance (IGT). Participants with IGT are at high risk for cardiovascular disease (CVD), with a marked increase in the number and severity of CVD risk factors. We prospectively assessed the impact of our interventions on hypertension, dyslipidemia, and CVD events. RESEARCH DESIGN AND METHODS - The study group consisted of 3,234 individuals with IGT randomly assigned to receive intensive lifestyle intervention, metformin, or placebo. Annual assessment of blood pressure, lipids, electrocardiogram, and CVD events was undertaken. RESULTS - Hypertension was present in 30% of participants at study entry and then increased in the placebo and metformin groups, although it significantly decreased with intensive lifestyle intervention. Triglyceride levels fell in all treatment groups, but fell significantly more with intensive lifestyle intervention. Total cholesterol and LDL cholesterol levels were similar among treatment groups. Intensive lifestyle intervention significantly increased the HDL cholesterol level and reduced the cumulative incidence of the proatherogenic LDL phenotype B. At 3 years of follow-up, the use for pharmacologic therapy to achieve established goals in the intensive lifestyle group was 27-28% less for hypertension and 25% less for hyperlipidemia compared with placebo and metformin groups. Over an average of 3 years, 89 CVD events from 64 participants were positively adjudicated studywide, with no differences among treatment groups. CONCLUSIONS - Lifestyle intervention improves CVD risk factor status compared with placebo and metformin therapy. Although no differences in CVD events were noted after 3 years, achieved risk factor modifications suggest that longer intervention may reduce CVD event rates.

AB - OBJECTIVE - The Diabetes Prevention Program demonstrated the ability to delay or prevent type 2 diabetes in participants with impaired glucose tolerance (IGT). Participants with IGT are at high risk for cardiovascular disease (CVD), with a marked increase in the number and severity of CVD risk factors. We prospectively assessed the impact of our interventions on hypertension, dyslipidemia, and CVD events. RESEARCH DESIGN AND METHODS - The study group consisted of 3,234 individuals with IGT randomly assigned to receive intensive lifestyle intervention, metformin, or placebo. Annual assessment of blood pressure, lipids, electrocardiogram, and CVD events was undertaken. RESULTS - Hypertension was present in 30% of participants at study entry and then increased in the placebo and metformin groups, although it significantly decreased with intensive lifestyle intervention. Triglyceride levels fell in all treatment groups, but fell significantly more with intensive lifestyle intervention. Total cholesterol and LDL cholesterol levels were similar among treatment groups. Intensive lifestyle intervention significantly increased the HDL cholesterol level and reduced the cumulative incidence of the proatherogenic LDL phenotype B. At 3 years of follow-up, the use for pharmacologic therapy to achieve established goals in the intensive lifestyle group was 27-28% less for hypertension and 25% less for hyperlipidemia compared with placebo and metformin groups. Over an average of 3 years, 89 CVD events from 64 participants were positively adjudicated studywide, with no differences among treatment groups. CONCLUSIONS - Lifestyle intervention improves CVD risk factor status compared with placebo and metformin therapy. Although no differences in CVD events were noted after 3 years, achieved risk factor modifications suggest that longer intervention may reduce CVD event rates.

UR - http://www.scopus.com/inward/record.url?scp=15944424370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15944424370&partnerID=8YFLogxK

U2 - 10.2337/diacare.28.4.888

DO - 10.2337/diacare.28.4.888

M3 - Article

C2 - 15793191

AN - SCOPUS:15944424370

VL - 28

SP - 888

EP - 894

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 4

ER -